SEARCH · PubMed Health

Results for “Virginiamycin”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources

PubMed1996

Stereospecific reduction of virginiamycin M1 as the virginiamycin resistance pathway in Streptomyces virginiae.

In a cell extract of Streptomyces virginiae, virginiamycin M1 was inactivated in the presence of NADPH, while virginiamycin S remained intact. The inactivated product of virginiamycin M1 was isolated, and structure analysis revealed that the inactivation involves reduction of a C-16 carbonyl group leading to the formation of 16-dihydrovirginiamycin M1. Acetonide and benzylidene acetal derivatives were synthesized from the two hydroxyl groups on C-14 and C-16, and the C-16 stereochemistry was determined by 13C nuclear magnetic resonance spectroscopy. Two methyl groups of the acetonide derivative gave 13C signals of 20.1 and 30.1 ppm, indicating that the relative stereochemistry of the C-14 and C-16 hydroxy groups is syn. Furthermore, irradiation of the benzylidene methine proton gave clear nuclear Overhauser effect enhancement of the C-14 or C-16 methine protons, indicating that H-14 and H-16 were in an axial configuration. From the (14S) absolute configuration of natural virginiamycin M1 and the syn relative configuration for the C-14 and C-16 hydroxyl groups of the inactivated product, the C-16 absolute configuration of the inactivated product was thus identified as R.

Anti-Bacterial Agents↗

PubMed2000

Identification of an AfsA homologue (BarX) from Streptomyces virginiae as a pleiotropic regulator controlling autoregulator biosynthesis, virginiamycin biosynthesis and virginiamycin M1 resistance.

Virginiae butanolide (VB)-BarA of Streptomyces virginiae is one of the newly discovered pairs of a gamma-butyrolactone autoregulator and the corresponding receptor protein of the Streptomyces species, and has been shown to regulate the production of antibiotic virginiamycin (VM) in S. virginiae. A divergently transcribed barX gene is situated 259 bp upstream of the barA gene, and the BarX protein has been shown to be highly homologous (39.8% identity, 74. 6% similarity) to S. griseus AfsA. Although AfsA is thought to be a biosynthetic enzyme for A-factor, another member of the family of gamma-butyrolactone autoregulators, the in vivo function of S. virginiae BarX was investigated in this study by phenotypic and transcriptional comparison between wild-type S. virginiae and a barX deletion mutant. With the same growth rate as wild-type S. virginiae on both solid and liquid media, the barX mutant showed no apparent changes in its morphological behaviour, indicating that barX does not participate in morphological control in S. virginiae. However, the barX mutant became more sensitive to virginiamycin M1 than did the wild-type strain (minimum inhibitory concentration, 50 microgram ml-1 compared with > 200 microgram ml-1) and exhibited reduced VB and VM production. The VM production was not restored by exogenous addition of VB, suggesting that BarX per se is not a biosynthetic enzyme of VBs but a pleiotropic regulatory protein controlling VB biosynthesis. DNA sequencing of a 5.6 kbp downstream region of barX revealed the presence of five open reading frames (ORFs): barZ, encoding a BarB-like regulatory protein; orf2, encoding a Streptomyces coelicolor RedD-like pathway specific regulator; varM, encoding a homologue of ATP-dependent transporters for macrolide antibiotics; orf4, encoding a homologue of beta-ketoacyl ACP/CoA reductase; and orf5, encoding a homologue of dNDP-glucose dehydratase. Reverse transcription polymerase chain reaction (RT-PCR) analyses of the downstream five genes together with those of the three upstream genes (barA, barB, encoding a regulatory protein; and varS, encoding a virginiamycin S specific transporter) revealed that, in the barX mutant, the transcriptions of barZ, orf2, varM and orf5 were completely repressed and those of barB and varS were derepressed. Because free BarA (BarA in the absence of VB) in wild-type S. virginiae represses the transcription of bicistronic barB-varS operon through binding to a specific DNA sequence (BarA-responsive element, BARE) overlapping the barB transcriptional start site, the derepression of barB-varS transcription in the barX mutant suggested that the in vivo function of BarA was impaired by the lack of BarX protein. Gel-shift assays revealed that BarA easily lost its DNA-binding activity in the absence of BarX but that the defect was restored by the presence of recombinant BarX as a fusion with maltose-binding protein (MBP-BarX), whereas MBP-BarX itself showed no DNA-binding activity, indicating that BarX is likely to be a co-repressor of BarA, enforcing the DNA-binding activity of BarA through protein-protein interactions.

Bacterial Proteins↗

PubMedDate not supplied

Biosynthesis of antibiotics of the virginiamycin family, 5. The conversion of phenylalanine to phenylglycine in the biosynthesis of virginiamycin S1.

Conversion of L-phenylalanine to L-phenylglycine in the biosynthesis of virginiamycin S1 (1) can, in principle, take place with intramolecular nitrogen transfer or with intermolecular nitrogen transfer. A labeling experiment with DL-[3-13C, 15N]phenylalanine showed that the resulting L-phenylglycine contained no labeled nitrogen, indicating that the rearrangement proceeds via an intermolecular pathway.

Chemical Phenomena↗

PubMed2005

Effects of virginiamycin and a mannanoligosaccharide-virginiamycin shuttle program on the growth and performance of large white female turkeys.

Shuttle programs involving dietary supplementation of mannanoligosaccharides (MOS) and virginiamycin (VM) were evaluated in turkeys by their effects on growth performance, body weight uniformity, and carcass yield characteristics. Diets containing no growth promoter (control), VM (22 mg/kg), or a shuttle program (MOS-VM) of MOS (0 to 6 wk of age at 500 mg/ kg) and VM (6 to 14 wk of age at 22 mg/kg) were fed to Hybrid female turkeys. All diets were formulated to exceed NRC nutrient requirements. Each treatment was assigned to 8 replicate floor pens containing 20 birds that were reared from 1 to 98 d of age. Body weights and feed consumption were recorded at 3-wk intervals, and mortality and culled birds were recorded daily. At the conclusion of the trial, 2 birds per pen were randomly chosen for carcass yield analysis. Feeding VM alone significantly (P < 0.05) increased body weight compared with control fed birds during all periods. The MOS-VM shuttle program resulted in early growth depression for birds less than 3 wk of age, possibly influenced by an unplanned cold stress, but better growth than the nonmedicated control birds after 6 wk of age. Birds fed VM had superior (P < 0.05) feed conversion ratio from 0 to 3 wk, which persisted until 14 wk (P < 0.10). There were no treatment effects on overall feed consumption, uniformity, mortality, or cull rate. Processing yields or weight of various parts were also unaffected by treatment.

Aging↗

PubMed1981

Competition between erythromycin and virginiamycin for in vitro binding to the large ribosomal subunit.

When the S component of virginiamycin binds in vitro to the 50 S ribosomal subunit, a change of fluorescence intensity proportional to the amount of complex formed occurs. Erythromycin competes with virginiamycin S for attachment to ribosomes, and removes previously bound virginiamycin S from its target, as revealed by spectrofluorimetric analysis. The 50 S subunits which are incubated with the M component of virginiamycin (50 S*) have an increased affinity for virginiamycin S (the association constants of virginiamycin S with ribosomes are 2.5 x 10(6) M-1 in the absence of virginiamycin M, and 15 x 10(6) M-1 in its presence). Erythromycin does not compete with virginiamycin S for attachment to 50 S* subunits nor is it able to remove virginiamycin S previously bound to the 50 S* subunit. Thus, virginiamycin M produces a change in ribosomes, which results in a tighter complex virginiamycin S-50 S* subunit. Such change does not require the presence of virginiamycin M, however, as shown by the observation that ribosomes to which labeled virginiamycin M is transiently linked bind virginiamycin S in a form that cannot be removed by erythromycin.

Binding Sites↗

PubMed1984

Analysis of fluorescence quenching of ribosome-bound virginiamycin S.

The two virginiamycin components VM and VS interact synergistically with bacterial ribosomes in vitro and in vivo. Ribosome affinity for virginiamycin S increases about 10-fold upon incubation with virginiamycin M. This effect has been previously traced by spectrofluorimetric measurement based on the enhancement of virginiamycin S fluorescence upon its binding to the 50 S ribosomal subunit. In the present work the action of two virginiamycin S fluorescence quenchers, acrylamide and iodide, has been explored to gather information about the accessibility of ribosome-bound virginiamycin S and the variation of the accessibility level in the presence of virginiamycin M. Both acrylamide (non-ionized quencher) and iodide (ionized quencher) proved powerful quenchers of free virginiamycin S solutions. Since a comparable effect was obtained on 3- hydroxypicolinamide , the latter was indicated as the part of the molecule involved in the fluorescence effect. Fluorescence quenching by either agent was of the dynamic, i.e. collisional, type. Such an inference was based on the fact that these quenchers merely modified the emission spectrum (not the absorption spectrum), the bimolecular rate constant for the quenching process decreased linearly with the viscosity of the medium (static-type quenching is viscosity-independent), and that linear Stern-Volmer plots were obtained. The quenching ability of both agents underwent a sharp decrease in the presence of ribosomes; however, the Stern-Volmer equation was followed only in the case of acrylamide, whereas Lehrer 's relationship had to be applied in the case of iodide. When ribosomes were incubated with virginiamycin M, the fluorescence quenching ability of acrylamide and iodide was significantly reduced. Conclusions are as follows: a) the 3- hydroxypicolinyl residue of virginiamycin S is buried within an open well on the ribosome surface and is likely to be involved in the interaction with the binding site; b) the accessibility to the well is partly controlled by electrostatic forces; c) interaction of ribosomes with virginiamycin M entails a conformational change whereby the access to the well is reduced. These findings provide a molecular explanation for the previously observed increase of the association constant of virginiamycin S to ribosomes incubated with virginiamycin M which was found to be due to the decrease of the dissociation rate constant (the association rate constant remains practically the same).

Anti-Bacterial Agents↗

PubMed1995

[The effect of virginiamycin on rumen fermentation in vitro after adaptation of donors to the inoculum].

Virginiamycin is an antibiotic active against grampositive bacteria in the alimentary tract, which is also suitable for supplementation of diets of growing and finishing ruminants. The aim of this work was to specify the effect of virginiamycin on some parameters of rumen fermentation in vitro with inoculi taken from wethers adapted or non-adapted to the virginiamycin intake. Incubations were performed anaerobically at 39 degrees C in serum bottles closed with Bunsen valves. Virginiamycin was added at 0 or 10 mg/l to the rumen fluid diluted with McDougall buffer. Virginiamycin significantly decreased production and utilization of lactic acid, production of methane and decomposition of casein when rumen fluid was taken from non-adapted wethers. Most of its effects disappeared when rumen fluid was sampled from wethers adapted to the virginiamycin intake (100 mg per head daily for 2 months). Adaptation of wethers to virginiamycin was further confirmed by analyses of the rumen fluid which was used for inoculation of in vitro cultures. Molar percentages of acetate, propionate, butyrate and valerate were the same before and after the adaptation. Therefore it can be concluded that the effects of virginiamycin on rumen parameters are not stable and its addition to ruminant diets cannot be recommended, with exception of the milk nutrition period. In the last experiment the stability of virginiamycin in the rumen fluid of adapted wethers was investigated.(ABSTRACT TRUNCATED AT 250 WORDS)

Adaptation, Physiological↗

PubMed1998

Gene replacement analysis of the Streptomyces virginiae barA gene encoding the butyrolactone autoregulator receptor reveals that BarA acts as a repressor in virginiamycin biosynthesis.

Virginiae butanolides (VBs), which are among the butyrolactone autoregulators of Streptomyces species, act as a primary signal in Streptomyces virginiae to trigger virginiamycin biosynthesis and possess a specific binding protein, BarA. To clarify the in vivo function of BarA in the VB-mediated signal pathway that leads to virginiamycin biosynthesis, two barA mutant strains (strains NH1 and NH2) were created by homologous recombination. In strain NH1, an internal 99-bp EcoT14I fragment of barA was deleted, resulting in an in-frame deletion of 33 amino acid residues, including the second helix of the probable helix-turn-helix DNA-binding motif. With the same growth rate as wild-type S. virginiae on both solid and liquid media, strain NH1 showed no apparent changes in its morphological behavior, indicating that the VB-BarA pathway does not participate in morphological control in S. virginiae. In contrast, virginiamycin production started 6 h earlier in strain NH1 than in the wild-type strain, demonstrating for the first time that BarA is actively engaged in the control of virginiamycin production and implying that BarA acts as a repressor in virginiamycin biosynthesis. In strain NH2, an internal EcoNI-SmaI fragment of barA was replaced with a divergently oriented neomycin resistance gene cassette, resulting in the C-terminally truncated BarA retaining the intact helix-turn-helix motif. In strain NH2 and in a plasmid-integrated strain containing both intact and mutated barA genes, virginiamycin production was abolished irrespective of the presence of VB, suggesting that the mutated BarA retaining the intact DNA-binding motif was dominant over the wild-type BarA. These results further support the hypothesis that BarA works as a repressor in virginiamycin production and suggests that the helix-turn-helix motif is essential to its function. In strain NH1, VB production was also abolished, thus indicating that BarA is a pleiotropic regulatory protein controlling not only virginiamycin production but also autoregulator biosynthesis.

4-Butyrolactone↗

PubMed1999

Effects of feeding virginiamycin and sodium bicarbonate to grazing lactating dairy cows.

The effects of virginiamycin, an agent active against Gram-positive lactic acid-producing bacteria, and NaHCO3 on ruminal and fecal pH, rumen volatile fatty acid proportions, blood metabolites, and milk production and composition were assessed. This study was conducted over 28 d and involved 71 dairy cows that grazed predominantly ryegrass, oats, and clover, and that were fed 10 kg of concentrate pellets/d per head. The pellets contained (per kilogram) no dietary additive, 30 mg of virginiamycin, 20 g of NaHCO3, or 30 mg of virginiamycin and 20 g of NaHCO3 on a DM basis. Ruminal pH tended to be higher in cows fed pellets containing virginiamycin (7.0 vs. 6.9; SED = 0.16). The results of in vitro incubation of ruminal fluid with glucose found the potential for L-lactic acid accumulation in ruminal fluid to be significantly lower in cows fed virginiamycin (15.5 vs. 35.3 mmol/L; SED = 2.98). Cows fed virginiamycin had significantly higher fecal pH (6.72 vs. 6.57; SED = 0.08) and produced more milk (23.94 vs. 23.32 kg/d) and more lactose than those not fed virginiamycin. No effects of NaHCO3 on fecal pH, in vitro potential for L-lactic acid accumulation in ruminal fluid, or milk production were observed, but ruminal pH tended to be higher and ruminal acetate proportion was greater for cows fed NaHCO3. Milk fat and milk protein percentage did not differ significantly as a result of dietary treatment. These data suggest that the inclusion of virginiamycin in the diet will reduce L-lactic acid accumulation in ruminal fluid and increase fecal pH in grazing dairy cattle fed concentrate supplements.

Animal Feed↗

PubMed2003

Antimicrobial resistance in swine and chickens fed virginiamycin for growth promotion.

In a prospective controlled study, we evaluated pigs (5-month period) and chickens (11-week period) fed subtherapeutic levels of virginiamycin. A total of 13 Enterococcus faecium were isolated from 10 pigs and 17 from 8 chickens. There were 8 pulsed-field gel electrophoresis (PFGE) patterns in E. faecium isolates from pigs and 17 from chickens. Resistance to quinupristin/dalfopristin resistance occurred in 2 of 13 E. faecium from pigs and 2 of 17 E. faecium from chickens. There were no strains exhibiting high-level gentamicin (MIC> or =2000 microg/ml) or vancomycin resistance. There was no relative weight gain in animals that received virginiamycin. The mean weight increase for the pigs in the group fed virginiamycin was 107.6 lb vs. 126.4 lb in the group that did not receive virginiamycin (P=n.s.). Chickens fed virginiamycin had a mean weight increase of 1672 g vs. 1886 g in the group that did not receive virginiamycin (P=n.s.). There was no correlation between receipt of virginiamycin or weight gain and presence of quinupristin/dalfopristin-resistant strains.

Animals↗

PubMed1986

Localization of virginiamycin S binding site on bacterial ribosome by fluorescence energy transfer.

Virginiamycin S, a type B synergimycin inhibiting protein synthesis in bacteria, competes with erythromycin for binding to the 50S ribosomal subunits; the mechanism of action of the two antibiotics is unclear. Energy-transfer experiments between virginiamycin S (which is endowed with inherent fluorescence due to its hydroxypicolinyl moiety) and fluorescent coumarinyl derivatives of ribosomal proteins L7 and L10 have been carried out to locate the binding site of this antibiotic on the ribosome. Previous studies have indicated that two L7/L12 dimers can attach respectively to a strong binding site located on the central protuberance and to a weak binding site located on the stalk of the 50S subunits and that protein L10 is located at the base of the stalk. The distance between ribosome-bound virginiamycin S and a fluorophore located at the strong binding site of proteins L7/L12 (Lys-51 of L7) was found to be 56 (+/- 15) A. Virginiamycin S, on the other hand, was located at a distance exceeding 67 A from the weak binding site of L7/L12 dimers. A fluorophore positioned on the unique cysteine (Cys-70) of protein L10 and ribosome-bound virginiamycin S proved to be more than 60 A apart. From data available on the location of proteins L7/L12 and L10, a model is proposed, whereby the virginiamycin S binding site is placed at the base of the central protuberance of the 50S subunits, in proximity of the presumptive peptidyl transferase center. The binding sites of macrolides and lincosamides (related antibiotics of the MLS group) are expected to be very close to that of virginiamycin S.

Binding Sites↗

PubMed1990

Affinity labeling of the virginiamycin S binding site on bacterial ribosome.

Virginiamycin S (VS, a type B synergimycin) inhibits peptide bond synthesis in vitro and in vivo. The attachment of virginiamycin S to the large ribosomal subunit (50S) is competitively inhibited by erythromycin (Ery, a macrolide) and enhanced by virginiamycin M (VM, a type A synergimycin). We have previously shown, by fluorescence energy transfer measurements, that virginiamycin S binds at the base of the central protuberance of 50S, the putative location of peptidyltransferase domain [Di Giambattista et al. (1986) Biochemistry 25, 3540-3547]. In the present work, the ribosomal protein components at the virginiamycin S binding site were affinity labeled by the N-hydroxysuccinimide ester derivative (HSE) of this antibiotic. Evidence has been provided for (a) the association constant of HSE-ribosome complex formation being similar to that of native virginiamycin S, (b) HSE binding to ribosomes being antagonized by erythromycin and enhanced by virginiamycin M, and (c) a specific linkage of HSE with a single region of 50S, with virtually no fixation to 30S. After dissociation of covalent ribosome-HSE complexes, the resulting ribosomal proteins have been fractionated by electrophoresis and blotted to nitrocellulose, and the HSE-binding proteins have been detected by an immunoenzymometric procedure. More than 80% of label was present within a double spot corresponding to proteins L18 and L22, whose Rfs were modified by the affinity-labeling reagent. It is concluded that these proteins are components of the peptidyltransferase domain of bacterial ribosomes, for which a topographical model, including the available literature data, is proposed.

Affinity Labels↗

PubMed1997

Use of virginiamycin to control the growth of lactic acid bacteria during alcohol fermentation.

The antibiotic virginiamycin was investigated for its effects on growth and lactic acid production by seven strains of lactobacilli during the alcoholic fermentation of wheat mash by yeast. The lowest concentration of virginiamycin tested (0.5 mg Lactrol kg-1 mash), was effective against most of the lactic acid bacteria under study, but Lactobacillus plantarum was not significantly inhibited at this concentration. The use of virginiamycin prevented or reduced potential yield losses of up to 11% of the produced ethanol due to the growth and metabolism of lactobacilli. However, when the same concentration of virginiamycin was added to mash not inoculated with yeast, Lactobacillus rhamnosus and L. paracasei grew after an extensive lag of 48 h and L. plantarum grew after a similar lag even in the presence of 2 mg virginiamycin kg-1 mash. Results showed a variation in sensitivity to virginiamycin between the different strains tested and also a possible reduction in effectiveness of virginiamycin over prolonged incubation in wheat mash, especially in the absence of yeast.

Anti-Bacterial Agents↗

PubMedDate not supplied

Response to virginiamycin in finishing beef bulls fed a maize silage diet or a complete dry feed.

Two experiments have been conducted to study the effect of virginiamycin in a maize silage diet (I) or a complete dry feed (II). Virginiamycin was incorporated at 0 or 65 mg per kg concentrate which was fed at 0.75% of the live weight of 43 Belgian white-red bulls (I), or at 0 or 25 mg per kg complete dry feed for 24 Belgian white-blue bulls (II). In the first experiment daily gain was increased by virginiamycin from 1.28 to 1.38 kg without effect on intake, but with an improved feed conversion from 5.99 to 5.60 kg dry matter/kg gain. In the second experiment daily gain, daily dry matter intake and feed conversion were not influenced by virginiamycin. The differences between experiments may suggest that the response to virginiamycin probably depends on the diet type, although no significant interaction was found between diet type and virginiamycin with regard to growth rate (P greater than 0.10). In both experiments, fasting weight loss, dressing percent and carcass classification and composition were not affected by virginiamycin.

Animal Feed↗

PubMed1991

Influence of virginiamycin on growth and efficiency of large white turkeys.

Efficacy of virginiamycin (22 mg/kg) in combination with no drug, amprolium, carbarsone, halofuginone, or monensin, was studied. Male and female turkeys were raised to market age in five experiments conducted from 1983 to 1987. Body weights and feed:gain responses to virginiamycin for males and females were positive and significant (P less than .05). Virginiamycin resulted in mean 5.2 and 6.3% body weight responses and 3.3 and 2.2% feed:gain responses for males at 19 or 20 wk of age and for females at 16 or 17 wk of age, respectively. Mortality rates were low in all studies, and were not influenced by virginiamycin. In a processing study, virginiamycin in combination with halofuginone did not affect shrinkage, yield, or market grade. Feed was utilized by males and females 3.9 and 3.0%, respectively, more efficiently than expected with dietary virginiamycin, compared with results predicted by a simulation modeling technique. Profitability was considerably greater with dietary virginiamycin using actual data than with simulated feed consumption data.

Amebicides↗

PubMed1983

The lasting ribosome alteration produced by virginiamycin M disappears upon removal of certain ribosomal proteins.

Transient incubation of bacterial ribosomes with virginiamycin M produces a lasting damage of 50 S ribosomal subunits, whereby the elongation of peptide chains is still blocked after removal of the antibiotic. To elucidate the mechanism of this inactivation, ribosomal proteins were stepwise removed from 50 S subunits previously incubated with virginiamycin M, and cores were submitted to three functional tests. Total removal of proteins L7, L8, L12 and L16, and partial removal of L6, L9, L10 and L11, resulted in a loss of the virginiamycin M-induced alteration. When the split protein fractions were added back to these cores, unaltered functional particles were obtained. The reconstituted subunits, on the other hand, proved fully sensitive to virginiamycin M in vitro as they underwent, upon transient contact with the antibiotic, an alteration comparable to that of native particles. It is concluded that the virginiamycin M-induced ribosome damage is due to the production of a stable conformational change of the 50 S subunit. These data parallel those of an accompanying paper (Cocito, C., Vanlinden, F. and Branlant, C. (1983) Biochim. Biophys. Acta 739, 158-163) showing the intactness of all rRNA species from ribosomes treated in vivo and in vitro with virginiamycin M.

Cell-Free System↗

PubMedDate not supplied

Effect of virginiamycin on in vivo digestibility, rumen fermentation and nitrogen balance.

Three experiments were conducted to investigate the effect of virginiamycin. Digestibility was determined with wethers, fed a diet of 0.65 maize silage and 0.35 concentrate on a dry matter basis (Experiment I) or a complete dry feed (Experiment II) at maintenance, and with growing bulls fed a maize silage diet ad libitum supplemented with 7.5 g concentrate per kg live weight (Experiment III). Virginiamycin was incorporated at 0 or 65 ppm in the concentrate and 0 or 25 ppm in the complete dry feed. No significant effect on dry or organic matter digestibility was observed, although digestibilities of protein and ether extract were reduced by virginiamycin in experiments I and II, respectively. Rumen fermentation was studied in experiments I and II. Virginiamycin increased acetic acid concentration and reduced butyric acid concentration in experiment I, but exerted no significant effect in experiment II. An interaction between diet type and virginiamycin was found for the C2/C3 ratio. Nitrogen balance, measured in experiment III, was not affected by virginiamycin.

Animal Feed↗

PubMed2006

Characterization of intestinal microbiota and response to dietary virginiamycin supplementation in the broiler chicken.

The inclusion of antibiotic growth promoters, such as virginiamycin, at subtherapeutic levels in poultry feeds has a positive effect on health and growth characteristics, possibly due to beneficial effects on the host gastrointestinal microbiota. To improve our understanding of the chicken gastrointestinal microbiota and the effect of virginiamycin on its composition, we characterized the bacteria found in five different gastrointestinal tract locations (duodenal loop, mid-jejunum, proximal ileum, ileocecal junction, and cecum) in 47-day-old chickens that were fed diets excluding or including virginiamycin throughout the production cycle. Ten libraries (five gastrointestinal tract locations from two groups of birds) of approximately 555-bp chaperonin 60 PCR products were prepared, and 10,932 cloned sequences were analyzed. A total of 370 distinct cpn60 sequences were identified, which ranged in frequency of recovery from 1 to 2,872. The small intestinal libraries were dominated by sequences from the Lactobacillales (90% of sequences), while the cecum libraries were more diverse and included members of the Clostridiales (68%), Lactobacillales (25%), and Bacteroidetes (6%). To assess the effects of virginiamycin on the gastrointestinal microbiota, 15 bacterial targets were enumerated using quantitative, real-time PCR. Virginiamycin was associated with increased abundance of many of the targets in the proximal gastrointestinal tract (duodenal loop to proximal ileum), with fewer targets affected in the distal regions (ileocecal junction and cecum). These findings provide improved profiling of the composition of the chicken intestinal microbiota and indicate that microbial responses to virginiamycin are most significant in the proximal small intestine.

Animals↗